Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Overview
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Companies Involved in Therapeutics Development
Avex Life Sciences Corp
AstraZeneca Plc
Karu Therapeutics Inc
Lan Sheng Biomedicine Suzhou Co Ltd
Lenz Therapeutics LLC
NeuroSolis Inc
Sosei Heptares
Suven Life Sciences Ltd
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Drug Profiles
(aceclidine + tropicamide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(trospium chloride + xanomeline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blarcamesine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CVL-231 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize CHRM4 for Drug-Induced Dyskinesia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HTL-0016878 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LS-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0527f - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0559 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NSX-0559f - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Muscarinic Acetylcholine Receptor M4 for Schizophrenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Muscarinic M1 and M4 Receptors for Unspecified Neurologic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Muscarinic Acetylcholine Receptor 4 for Psychosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0467154 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-6000918 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-6001852 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Dormant Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Discontinued Products
Muscarinic Acetylcholine Receptor M4 (CHRM4) - Product Development Milestones
Featured News & Press Releases
Jun 23, 2021: Karu Therapeutics announces results from phase 1b trial evaluating the safety and tolerability of KarXT in healthy elderly volunteers
Jun 21, 2021: Avex Life Sciences announces AVEX2-73 (Blarcamesine) biomarker correlated with efficacy endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome
Jun 14, 2021: Avex Life Sciences reports new publication in medical jourl elucidating the mechanism of AVEX2-73 (blarcamesine) related to the treatment of Alzheimer’s Disease
Jun 08, 2021: Avex Life Sciences announces exceeding of enrollment target for the precision medicine AVEX2-73 (blarcamesine) phase 2b/3 clinical trial in patients with Alzheimer’s Disease
Jun 03, 2021: Avex Life Sciences announces Notice of allowance for U.S. patent application AVEX2-73 (blarcamesine) for the treatment of cardiac dysfunctions
Apr 12, 2021: Avex Life Sciences reports the results of review by the Independent Data Safety Monitoring Board for its phase 2/3 trials of AVEX2-73 in patients with Rett syndrome
Mar 31, 2021: Avex Life Sciences reports data review by the Independent Data Safety Monitoring board for its phase 2b/3 clinical trial of AVEX2-73 in patients with Alzheimer’s Disease
Mar 16, 2021: Avex Life Sciences reports AVEX2-73 (blarcamesine) featured as a disease-modifying small molecule in phase 3 clinical trials in a new publication in medical jourl titled “Future Avenues for Alzheimer’s Disease Detection and Therapy”
Feb 24, 2021: Karu Therapeutics anounces New England Jourl of Medicine publication of data from EMERGENT-1 phase 2 trial evaluating KarXT in Schizophrenia
Jan 11, 2021: Avex Life Sciences receives Michael J. Fox Foundation grant for clinical study of AVEX2-73 (blarcamesine) in people with Parkinson’s Disease
Dec 21, 2020: Avex Life Sciences announces webir on Rett syndrome and AVEX2-73 (Blarcamesine) phase 2 data hosted by Ladenburg Thalmann & Co.
Dec 15, 2020: Avex Life Sciences announces AVEX2-73 (Blarcamesine) meets primary and secondary endpoints in placebo-controlled U.S. phase 2 clinical trial for the treatment of adult patients with Rett syndrome
Nov 30, 2020: Avex Life Sciences announces notice of allowance for U.S. Patent Application with expanding claims covering AVEX2-73 (blarcamesine) for the treatment of Rett Syndrome and other neurodevelopmental disorders
Nov 06, 2020: Proof of concept controlled phase 2 clinical trial data evaluating AVEX2-73 (blarcamesine) in Parkinson’s disease dementia presented at CTAD 2020 conference
Oct 15, 2020: Avex Life Sciences announces positive results from proof of concept controlled phase 2 clinical trial evaluating Avex 2-73 (blarcamesine) in Parkinson’s disease dementia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indication, 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Anavex Life Sciences Corp, 2021
Pipeline by AstraZeneca Plc, 2021
Pipeline by Karuna Therapeutics Inc, 2021
Pipeline by Lan Sheng Biomedicine Suzhou Co Ltd, 2021
Pipeline by Lenz Therapeutics LLC, 2021
Pipeline by NeuroSolis Inc, 2021
Pipeline by Sosei Heptares, 2021
Pipeline by Suven Life Sciences Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021